Post-commercialization, observational data from two movement-disorder clinics reporting on inhaled levodopa as a rapid rescue therapy for Parkinson's patients with motor fluctuations, focusing on real-world efficacy, tolerability, and practical use.

Provides useful translational/clinical evidence supporting inhaled levodopa for rapid OFF-episode relief and implementation in practice, aiding symptomatic treatment decisions though it does not advance disease-modifying mechanisms.